Abstract

Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype. Recent studies have shown that MHC class II (MHCII) expression and tumor infiltrating lymphocytes are important prognostic factors in patients with TNBC, although the relative importance of lymphocyte subsets and associated protein expression is incompletely understood. NanoString Digital Spatial Profiling (DSP) allows for spatially resolved, highly multiplexed quantification of proteins in clinical samples. In this study, we sought to determine if DSP could be used to characterize expression of MHCII and other immune related proteins in tumor epithelial versus stromal compartments of patient-derived TNBCs (N = 10) using a panel of 39 markers. We confirmed that a subset of TNBCs have elevated expression of HLA-DR in tumor epithelial cells; HLA-DR expression was also significantly higher in the tumors of patients with long-term disease-free survival when compared to patients that relapsed. HLA-DR expression in the epithelial compartment was correlated with high expression of CD4 and ICOS in the stromal compartment of the same tumors. We also identified candidate protein biomarkers with significant differential expression between patients that relapsed versus those that did not. In conclusion, DSP is a powerful method that allows for quantification of proteins in the immune microenvironment of TNBCs.

Highlights

  • Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype

  • We have shown that expression of MHC class II (MHCII) mRNA in clinical samples is correlated with the presence of tumor-infiltrating lymphocytes (TILs) and with elevated expression of TIL genes including CD3D, CD4, and CD8A3

  • We established that HLA-DR protein expression is significantly higher in the tumors of patients with long-term DFS compared to patients who relapsed

Read more

Summary

Introduction

Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype. Recent studies have shown that MHC class II (MHCII) expression and tumor infiltrating lymphocytes are important prognostic factors in patients with TNBC, the relative importance of lymphocyte subsets and associated protein expression is incompletely understood. Using RNA-seq of patient-derived TNBCs, we have shown that elevated expression of genes in the major histocompatibility complex Class II antigen presentation pathway (MHCII) is a favorable prognostic factor that is associated with long-term DFS2. This genomics discovery led us to develop and validate a clinical prognostic assay that measures expression of MHCII and tumor-infiltrating lymphocyte (TIL) genes in formalin-fixed, paraffin embedded (FFPE) clinical samples using NanoString technology[3]. We sought to determine if DSP can be used to characterize expression of MHCII and other immune related proteins in tumor epithelial versus stromal compartments of patient-derived TNBC samples

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call